Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 81 points (0.5%) at 17,082 as of Monday, Aug. 25, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,780 issues advancing vs. 1,159 declining with 188 unchanged.

The Drugs industry currently sits up 1.2% versus the S&P 500, which is up 0.4%. Top gainers within the industry include InterMune ( ITMN), up 35.4%, Incyte ( INCY), up 5.7%, Illumina ( ILMN), up 2.4%, Gilead ( GILD), up 2.3% and Sanofi ( SNY), up 2.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Celgene ( CELG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Celgene is up $1.77 (1.9%) to $93.39 on average volume. Thus far, 2.2 million shares of Celgene exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $92.12-$93.86 after having opened the day at $92.49 as compared to the previous trading day's close of $91.62.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $73.3 billion and is part of the health care sector. Shares are up 8.4% year-to-date as of the close of trading on Friday. Currently there are 17 analysts who rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, robust revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Celgene Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is up $0.57 (1.0%) to $59.74 on light volume. Thus far, 2.1 million shares of Merck exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $59.26-$59.87 after having opened the day at $59.31 as compared to the previous trading day's close of $59.17.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $169.8 billion and is part of the health care sector. Shares are up 18.2% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AbbVie ( ABBV) is up $0.60 (1.1%) to $55.80 on light volume. Thus far, 3.3 million shares of AbbVie exchanged hands as compared to its average daily volume of 10.1 million shares. The stock has ranged in price between $55.18-$55.92 after having opened the day at $55.40 as compared to the previous trading day's close of $55.20.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $87.5 billion and is part of the health care sector. Shares are up 4.5% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Global Stocks Slip as 3% 10-Year Yields, Tech Weakness Unsettle Markets

Global Stocks Slip as 3% 10-Year Yields, Tech Weakness Unsettle Markets

Akorn Plunges as Germany's Fresenius Ditches Takeover Amid Data Allegations

Akorn Plunges as Germany's Fresenius Ditches Takeover Amid Data Allegations

Stocks Sputter as U.S. 10-Year Yields Test 3% Amid Commodity-Led Inflation Spike

Stocks Sputter as U.S. 10-Year Yields Test 3% Amid Commodity-Led Inflation Spike